GH Research (GHRS)
14.04
0.05 (0.36%)
At close: Feb 20, 2025, 3:59 PM
14.00
-0.28%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 12.12 |
| Market Cap | 870.87M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.79 |
| PE Ratio (ttm) | -17.77 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.44 |
| Volume | 248,018 |
| Avg. Volume (20D) | 413,691 |
| Open | 13.90 |
| Previous Close | 13.99 |
| Day's Range | 13.77 - 14.49 |
| 52-Week Range | 6.00 - 20.50 |
| Beta | undefined |
About GHRS
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol GHRS
Website https://www.ghres.com
Analyst Forecast
According to 4 analyst ratings, the average rating for GHRS stock is "Buy." The 12-month stock price forecast is $33.5, which is an increase of 138.60% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 weeks ago
-9.28%
GH Research shares are trading lower after announc...
Unlock content with
Pro Subscription
2 weeks ago
+69.72%
GH Research shares are trading higher after the company's inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.
